CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. - Castagnoli L; Franceschini A; Cancila V; Dugo M; Bigliardi M; Chiodoni C; Toneguzzo P; Regondi V; Corsetto PA; Pietrantonio F; Mazzucchelli S; Corsi F; et al. (Journal of experimental & clinical cancer research : CR, 2025)